 MARLBOROUGH, Mass., April 29, 2021 PRNewswire -- Phio Pharmaceuticals Corp. Nasdaq: PHIO, a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi INTASYLTM therapeutic platform, today announced new data to be presented at the upcoming 24th Annual Meeting of the American Society of Gene Cell Therapy ASGCT, which is being held on May 11 - May 14, 2021, and the 2021 American Society of Clinical Oncology ASCO Annual Meeting, which is being held on June 4 - 8, 2021. 